Biocompatibility of a bicarbonate/lactate-buffered PD fluid tested with a double-chamber cell culture system

Peritoneal Dialysis International

Volumn 25, Issue 4, 2005, Pages 387-393

  Fusshoeller, Andreas ^a   Baehr, Jessica ^a   Grabensee, Bernd ^a   Plum, Joerg ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Bicarbonate; Biocompatibility; Cell culture model; Peritoneal mesothelial cells

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BICARBONATE; CA 125 ANTIGEN; DIALYSIS FLUID; INTERLEUKIN 6; LACTIC ACID; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BIOCOMPATIBILITY; BIOLOGICAL MODEL; CELL CULTURE; CELL FUNCTION; CELL ISOLATION; CELL VIABILITY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; FIBROSIS; HUMAN; HUMAN CELL; MESOTHELIUM CELL; PERITONEUM CELL; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 23744484197     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502500415     Document Type: Article

References (30)

1. Topley N, Alobaidi HM, Davies M, Coles GA, Williams JD, Lloyd D. The effect of dialysate on peritoneal phagocyte oxidative metabolism. Kidney Int 1988; 34:404-11.
2. Douvdevani A, Rapoport J, Konforti A, Zlotnik M, Chaimovitz C. The effect of peritoneal dialysis fluid on the release of IL-1 beta and TNF alpha by macrophages/monocytes. Perit Dial Int 1993; 13:112-17.
3. Plum J, Razeghi P, Lordnejad RM, Perniok A, Fleisch M, Fussholler A, et al. Peritoneal dialysis fluids with a physiologic pH based on either lactate or bicarbonate buffer-effects on human mesothelial cells. Am J Kidney Dis 2001; 38:867-75.
4. Jorres A, Bender TO, Finn A, Witowski J, Frohlich S, Gahl GM, et al. Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function. Kidney Int 1998; 54:2184-93.
5. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12:2434-41.
6. Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-57.
7. Lee JH, Reddy DK, Saran R, Moore HL, Twardowski ZJ, Nolph KD, et al. Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions. Perit Dial Int 2000; 20:643-51.
8. Breborowicz A, Martis L, Oreopoulos DG. Changes in biocompatibility of dialysis fluid during its dwell in the peritoneal cavity. Perit Dial Int 1995; 15:152-7.
9. Jorres A, Gahl GM, Frei U. Peritoneal dialysis fluid biocompatibility: does it really matter? Kidney Int Suppl 1994; 48:S79-86.
10. Feriani M. Bicarbonate-buffered CAPD solutions: from clinical trials to clinical practice. Perit Dial Int 1997; 17(Suppl 2):S51-5.
11. Lage C, Pischetsrieder M, Aufricht C, Jorres A, Schilling H, Passlick-Deetjen J. First in vitro and in vivo experiences with Stay-Safe Balance, a pH-neutral solution in a dual-chambered bag. Perit Dial Int 2000; 20(Suppl 5):S28-32.
12. Mactier RA, Sprosen TS, Gokal R, Withams PF, Lindbergh M, Naik RB, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998; 53:1061-7.
13. Jones S, Holmes CJ, Mackenzie RK, Stead R, Coles GA, Williams JD, et al. Continuous dialysis with bicarbonate/lactate-buffered peritoneal dialysis fluids results in a long-term improvement in ex vivo peritoneal macrophage function. J Am Soc Nephrol 2002; 13(Suppl 1):S97-103.
14. Topley N, Kaur D, Petersen MM, Jorres A, Williams JD, Faict D, et al. In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function. J Am Soc Nephrol 1996; 7:218-24.
15. Hekking LH, Zareie M, Driesprong BA, Faict D, Welten AG, de Greeuw L et al. Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate-buffered solution. J Am Soc Nephrol 2001; 12:2775-86.
16. Plum J, Hermann S, Fussholler A, Schoenicke G, Donner A, Rohrborn A, et al. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int Suppl 2001; 78:S42-7.
17. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11: 498-506.
18. Fussholler A, zur Nieden S, Grabensee B, Plum J. Peritoneal fluid and solute transport: influence of treatment time, peritoneal dialysis modality, and peritonitis incidence. J Am Soc Nephrol 2002; 13:1055-60.
19. Yang AH, Chen JY, Lin YP, Huang TP, Wu CW. Peritoneal dialysis solution induces apoptosis of mesothelial cells. Kidney Int 1997; 51:1280-8.
20. Stylianou E, Jenner LA, Davies M, Coles GA, Williams JD. Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int 1990; 37:1563-70.
21. Fusshoeller A, Plail M, Grabensee B, Plum J. Biocompatibility pattern of a bicarbonate/lactate buffered peritoneal dialysis fluid in APD - a prospective, randomized study. Nephrol Dial Transplant 2004; 19:2101-6.
22. Fussholler A, Grabensee B, Plum J. Effluent CA 125 concentration in chronic peritoneal dialysis patients: influence of PD duration, peritoneal transport and PD regimen. Kidney Blood Press Res 2003; 26:118-22.
23. Wieczorowska-Tobis K, Polubinska A, Schaub TP, Schilling H, Wisniewska J, Witowski J, et al. Influence of neutral-pH dialysis solutions on the peritoneal membrane: a long-term investigation in rats. Perit Dial Int 2001; 21(Suppl 3): S108-13.
24. Witowski J, Topley N, Jorres A, Liberek T, Coles GA, Williams JD. Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 1995; 47:282-93.
25. Pawlaczyk K, Kuzlan-Pawlaczyk M, Wieczorowska-Tobis K, Polubinska A, Wisniewska J, Faict D, et al. Bicarbonate/lactate dialysis solution improves in vivo function of peritoneal host defense in rats. Perit Dial Int 1999; 19(Suppl 2):S370-7.
26. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan JA, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348:403-13.
27. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529-38.
28. Visser CE, Brouwer-Steenbergen JJ, Betjes MG, Koomen GC, Beelen RH, Krediet RT. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 1995; 10:64-9.
29. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT. Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int 1997; 51:888-93.
30. Ha H, Yu MR, Lee HB. High glucose-induced PKC activation mediates TGF-beta 1 and fibronectin synthesis by peritoneal mesothelial cells. Kidney Int 2001; 59:463-70.